Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.
Yan XiongHolger GreschikCatrine JohanssonLudwig SeifertVicki GambleKwang-Su ParkVincent FaganFengling LiIrene ChauMasoud VedadiCheryl H ArrowsmithPaul BrennanOleg FedorovManfred JungGillian FarnieJing LiuUdo OppermannRoland SchüleJian JinPublished in: Journal of medicinal chemistry (2024)
The methyl-lysine reader protein SPIN1 plays important roles in various human diseases. However, targeting methyl-lysine reader proteins has been challenging. Very few cellularly active SPIN1 inhibitors have been developed. We previously reported that our G9a/GLP inhibitor UNC0638 weakly inhibited SPIN1. Here, we present our comprehensive structure-activity relationship study that led to the discovery of compound 11 , a dual SPIN1 and G9a/GLP inhibitor, and compound 18 (MS8535), a SPIN1 selective inhibitor. We solved the cocrystal structure of SPIN1 in complex with 11 , confirming that 11 occupied one of the three Tudor domains. Importantly, 18 displayed high selectivity for SPIN1 over 38 epigenetic targets, including G9a/GLP, and concentration dependently disrupted the interactions of SPIN1 and H3 in cells. Furthermore, 18 was bioavailable in mice. We also developed 19 (MS8535N), which was inactive against SPIN1, as a negative control of 18 . Collectively, these compounds are useful chemical tools to study biological functions of SPIN1.
Keyphrases
- room temperature
- density functional theory
- single molecule
- transition metal
- multiple sclerosis
- molecular dynamics
- gene expression
- endothelial cells
- induced apoptosis
- type diabetes
- stem cells
- mass spectrometry
- ms ms
- signaling pathway
- mesenchymal stem cells
- cancer therapy
- bone marrow
- metabolic syndrome
- cell therapy
- amino acid
- structure activity relationship
- single cell
- drug delivery
- insulin resistance
- functional connectivity
- protein protein